scholarly journals Involvement of NADPH oxidases in alkali burn-induced corneal injury

2016 ◽  
Vol 38 (1) ◽  
pp. 75-82 ◽  
Author(s):  
XUE-JUN GU ◽  
XIAN LIU ◽  
YING-YING CHEN ◽  
YAO ZHAO ◽  
MAN XU ◽  
...  
Author(s):  
Kun Zhang ◽  
Miao-Yu Guo ◽  
Qiu-Gen Li ◽  
Xiao-Hua Wang ◽  
Yu-Ying Wan ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-14
Author(s):  
Shanshan Wan ◽  
Wanju Yang ◽  
Yumiao Pan ◽  
Zhuoqun Rao ◽  
Yanning Yang

Background. G9a, a well-known methyltransferase, plays a vital role in biological processes. However, its role in corneal neovascularization (CoNV) remains unclear. Methods. In vitro and in vivo models were assessed in hypoxia-stimulated angiogenesis and in a mouse model of alkali burn-induced CoNV. Human umbilical vein endothelial cells (HUVECs) were cultured under hypoxic conditions and different reoxygenation times to identify the molecular mechanisms involved in this process. Results. In this study, we found that G9a was positively related to corneal alkali burn-induced injury. Inhibition of G9a with BIX 01294 (BIX) alleviated corneal injury, including oxidative stress and neovascularization in vivo. Similarly, inhibition of G9a with either BIX or small interfering RNA (siRNA) exerted an inhibitory effect on hypoxia/reoxygenation (H/R)-induced oxidative stress and angiogenesis in HUVECs. Moreover, our study revealed that ablation of reactive oxygen species (ROS) with N-acetyl-cysteine suppressed angiogenesis in HUVECs exposed to H/R stimulation. Furthermore, NADPH oxidase 4 (Nox4), which was positively associated with ROS production and angiogenesis, was elevated during H/R. This effect could be reversed through suppression of the transcription activity of G9a with BIX or siRNA. In addition, the Nrf2/HO-1 pathway, upstream of Nox4, was activated in both BIX-treated mice and G9a-inhibited HUVECs. Collectively, our results demonstrated that inhibition of G9a-alleviated corneal angiogenesis by inhibiting Nox4-dependent ROS production through the Nrf2/HO-1 signaling pathway. These findings indicate that G9a may be a valuable therapeutic target for CoNV.


2021 ◽  
Vol 203 ◽  
pp. 108399
Author(s):  
Jiande Li ◽  
Shaobo Du ◽  
Yongpeng Shi ◽  
Jiangyuan Han ◽  
Zhanyu Niu ◽  
...  

2015 ◽  
Vol 22 (1) ◽  
pp. 3 ◽  
Author(s):  
Minkoo Seo ◽  
Jun-Sub Choi ◽  
Chang Rho ◽  
Choun-Ki Joo ◽  
Suk Lee

Author(s):  
R. M. Simonyan ◽  
K. V. Simonyan ◽  
S. M. Feschyan ◽  
V. A. Chavushyan ◽  
G. M. Simonyan ◽  
...  

2019 ◽  
Vol 10 (3) ◽  
Author(s):  
Anastasia V Poznyak ◽  
Dmitry A Kashirskikh ◽  
Victoria A Khotina ◽  
Andrey V Grechko ◽  
Alexander N Orekhov

2019 ◽  
Vol 19 (1) ◽  
pp. 7-19 ◽  
Author(s):  
Xiao-Xiao Lu ◽  
Shao-Zhen Zhao

Background: As one of the main blinding ocular diseases, corneal blindness resulted from neovascularization that disrupts the angiogenic privilege of corneal avascularity. Following neovascularization, inflammatory cells are infiltrating into cornea to strengthen corneal injury. How to maintain corneal angiogenic privilege to treat corneal disease has been investigated for decades. Methodology: Local administration of viral and non-viral-mediated anti-angiogenic factors reduces angiogenic protein expression in situ with limited or free of off-target effects upon gene delivery. Recently, Mesenchymal Stem Cells (MSCs) have been studied to treat corneal diseases. Once MSCs are manipulated to express certain genes of interest, they could achieve superior therapeutic efficacy after transplantation. Discussion: In the text, we first introduce the pathological development of corneal disease in the aspects of neovascularization and inflammation. We summarize how MSCs become an ideal candidate in cell therapy for treating injured cornea, focusing on cell biology, property and features. We provide an updated review of gene-based therapies in animals and preclinical studies in the aspects of controlling target gene expression, safety and efficacy. Gene transfer vectors are potent to induce candidate protein expression. Delivered by vectors, MSCs are equipped with certain characters by expressing a protein of interest, which facilitates better for MSC-mediated therapeutic intervention for the treatment of corneal disease. Conclusion: As the core of this review, we discuss how MSCs could be engineered to be vector system to achieve enhanced therapeutic efficiency after injection.


Sign in / Sign up

Export Citation Format

Share Document